Roche is a pharmaceutical and diagnostics company that focuses on improving people’s lives.
Roche is a pharmaceutical and diagnostics company that focused on improving people’s lives. Roche is the owner of F. Hoffmann-La Roche Ltd.Roche is a provider of in-vitro diagnostics and drugs for cancer and transplantation. It specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. F. Hoffmann-La Roche Ltd. serves hospitals, research labs, private medical labs, practicing physicians, and patients.Its products include cancer treatments, such as Avastin, Herceptin, and MabThera which are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. F. Hoffmann-La Roche Ltd. also conducts research and development as well as production related to molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostics and research.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 4, 2021 | Post-IPO Equity | $5B | 1 | SoftBank | — | Detail |
May 6, 2020 | Post-IPO Equity | $500K | 1 | SCALE AI | — | Detail |
Jan 1, 2010 | Post-IPO Equity | — | — | — | — | Detail |
Mar 14, 2003 | IPO | — | — | — | — | Detail |
May 8, 2001 | Post-IPO Equity | $2.79B | 1 | Novartis | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 8, 2022
Metagood
|
Pre-seed | $5M | Cryptocurrency | — |
Jan 17, 2022
Wilder World
|
Series Unknown | $30M | 3D Technology | — |
Jan 11, 2022
Freenome
|
Corporate Round | $290M | Biotechnology | Yes |
Dec 15, 2021
Forethought
|
Series C | $65M | Artificial Intelligence | — |
Nov 16, 2021
Fireside
|
Seed | $10M | Broadcasting | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SoftBank | Yes | Post-IPO Equity |
SCALE AI | Yes | Post-IPO Equity |
Novartis | Yes | Post-IPO Equity |
Roche has had 3 exits. Roche most notable exits include C4 Therapeutics , Flatiron Health
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Oct 1, 2020 | C4 Therapeutics | IPO | Health Diagnostics | Detail |
Feb 15, 2018 | Flatiron Health | M&A | Biotechnology | Detail |
Sep 12, 2014 | Affimed | IPO | Biotechnology | Detail |
Roche has acquired 51 organizations. Their most recent acquisition was Syntex Corporation on May 3, 1994. They acquired Syntex Corporation for $5.30B.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
May 3, 1994
Syntex Corporation
|
Health Diagnostics | acquisition | $ 5.30B | Detail |
Apr 29, 1995
Roche Biomedical Laboratories Inc.
|
Biotechnology | acquisition | — | Detail |
May 27, 1997
Boehringer Mannheim
|
Biotechnology | acquisition | $ 11B | Detail |
Feb 10, 2003
Disetronic Holding AG
|
Health Care | acquisition | — | Detail |
Jul 19, 2005
Roche Glycart
|
Biotechnology | acquisition | — | Detail |